纽维克蒂斯制药
NVCT
18.60
-0.33
-1.74%
纽维克蒂斯制药
US · NVCT
#3557 按市值排名
上市于 2022
18.60
-0.33
-1.74%
实时 - 追踪5344个代码 - 心跳于206秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了4.9个百分点。
机构持股
- 机构持股比例
- 33.73% -4.91pp
- 机构数量
- 105 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider34.92%
Mutual Fund19.25%
Hedge Fund9.06%
VC/PE Fund3.84%
Private Company1.07%
Public Company0.21%
Insurance Company0.13%
Government Pension Fund0.12%
Other31.35%
主要股东 截至 2026-06-30
Ron Bentsur
11.32% · 3.69M 股
Charles Mosseri-Marlio
10.12% · 3.30M 股
Enrique Poradosu
5.54% · 1.81M 股
Shay Shemesh
5.50% · 1.79M 股
Tang Capital Management, LLC
4.76% · 1.55M 股
Soleus Capital Management, L.P.
4.60% · 1.50M 股
BlackRock
3.07% · 1.00M 股
Vanguard Capital Management, LLC
3.07% · 1.00M 股
Perceptive Advisors LLC
3.07% · 1.00M 股
Iridian Asset Management LLC
2.39% · 777.08K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪46份申报 · 44次买入 · 1次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Ron Bentsur | Chairperson & CEO | 11.32% |
| Charles Mosseri-Marlio | -- | 10.12% |
| Enrique Poradosu | Co-Founder, Executive VP, Chief Scientific & Business Officer | 5.54% |
| Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 5.50% |
| Michael Carson | Officer | 0.71% |
| Kenneth Hoberman | Independent Director | 0.52% |
| Matthew Kaplan | Independent Director | 0.49% |
| James Oliviero | Independent Director | 0.38% |
| Juan Sanchez | Director | 0.35% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-02 | Michael Carson | Officer | Other Acquisition | +30,000 | -- |
| 2026-06-29 | Ron Bentsur | Chairperson & CEO | Open Market Acquisition | +12,500 | $20.00 |
| 2026-06-29 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +50,000 | $18.32 |
| 2026-06-10 | James Oliviero | Independent Director | Other Acquisition | +35,000 | -- |
| 2026-06-10 | Matthew Kaplan | Independent Director | Other Acquisition | +35,000 | -- |
| 2026-06-10 | Juan Sanchez | Director | Other Acquisition | +35,000 | -- |
| 2026-06-10 | Kenneth Hoberman | Independent Director | Other Acquisition | +35,000 | -- |
| 2026-01-05 | Ron Bentsur | Chairperson & CEO | Other Acquisition | +150,000 | -- |
| 2026-01-05 | Enrique Poradosu | Co-Founder, Executive VP, Chief Scientific & Business Officer | Other Acquisition | +150,000 | -- |
| 2026-01-05 | Michael Carson | Officer | Other Acquisition | +61,200 | -- |
| 2026-01-05 | Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | Other Acquisition | +150,000 | -- |
| 2025-11-04 | Ron Bentsur | Chairperson & CEO | Open Market Acquisition | +5,000 | $5.72 |
| 2025-11-04 | Matthew Kaplan | Independent Director | Open Market Acquisition | +11,000 | $5.84 |
| 2025-11-04 | Juan Sanchez | Director | Open Market Acquisition | +13,000 | $5.79 |
| 2025-10-26 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +154,770 | $6.06–6.28 |
| 2025-09-21 | Juan Sanchez | Director | Other Acquisition | +30,000 | -- |
| 2025-09-21 | Juan Sanchez | Director | Initial Statement of Beneficial | 0 | -- |
| 2025-06-19 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +5,603 | $7.99 |
| 2025-06-17 | Charles Mosseri-Marlio | -- | Open Market Acquisition | +33,442 | $8.05–8.11 |
| 2025-06-11 | James Oliviero | Independent Director | Other Acquisition | +30,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
纽维克蒂斯制药 讨论区 0 条评论